Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 2,481 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Renal Failure Clear all
Completed Phase 2 Interventional

Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis

NCT00704483
View directory record Official record
Conditions
Hyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy
Interventions
SBR759, Sevelamer HCl
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
19
States / cities
Chula Vista, California • La Mesa, California • Whittier, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 21, 2026, 10:14 AM EDT
Completed No phase listed Observational

Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus

NCT03413722
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Tacrolimus, Everolimus
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Oct 21, 2026, 10:14 AM EDT
Completed No phase listed Observational

Immune Development in Pediatric Transplantation (IMPACT)

NCT00951353
View directory record Official record
Conditions
Chronic Kidney Failure, End Stage Renal Disease
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 20 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
3
States / cities
Los Angeles, California • Palo Alto, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Oct 21, 2026, 10:14 AM EDT
Terminated No phase listed Observational

Post-Market Observation Study of Intra-renal Drug Delivery (PROVIDE)

NCT01064895
View directory record Official record
Conditions
Acute Kidney Injury, Acute Renal Failure, Renal Failure Chronic Contrast Induced, Chronic Kidney Disease
Interventions
Benephit catheter for Targeted Renal Therapy
Device
Lead sponsor
Angiodynamics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
15
States / cities
Miami, Florida • Miramar, Florida • Blackfoot, Idaho + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2016 · Synced Oct 21, 2026, 10:14 AM EDT
Terminated Phase 4 Interventional Results available

A Study to Explore the Renal Safety of Visipaque Injection 320 mgI/mL in Patients With Chronic Kidney Disease

NCT03119662
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Visipaque, Placebos
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
17
States / cities
Birmingham, Alabama • Mesa, Arizona • Little Rock, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 21, 2026, 10:14 AM EDT
Recruiting Not applicable Interventional

POCUS-Guided Diuresis for Decompensated Heart Failure

NCT06921603
View directory record Official record
Conditions
Heart Decompensation, Acute, Acute Kidney Injuries
Interventions
Furosemide (Standard Diuretic) Treatment, POCUS-Assessed Diuretic Management
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 21, 2026, 10:14 AM EDT
Active, not recruiting Phase 4 Interventional

Immunogenicity of HPV Vaccine in Transplant Recipients.

NCT05557370
View directory record Official record
Conditions
Chronic Kidney Diseases, Kidney Transplant
Interventions
Human Papilloma Virus vaccine (GARDASIL 9)
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Not applicable Interventional

The ReModel IHC Study for ESRD Patients

NCT05039541
View directory record Official record
Conditions
Dialysis Access Malfunction
Interventions
Alio Device
Device
Lead sponsor
Alio, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Sep 22, 2023 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How the Body Processes the Study Medicine Called PF-07923568 in People With Loss of Kidney Function

NCT06037031
View directory record Official record
Conditions
Renal Impairment
Interventions
Drug: PF-07923568
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
6
States / cities
Orlando, Florida • Tampa, Florida • Saint Paul, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 21, 2026, 10:14 AM EDT
Recruiting Phase 2Phase 3 Interventional

Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile

NCT03321656
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Tacrolimus, Envarsus XR
Drug
Lead sponsor
Roberto Gedaly
Other
Eligibility
18 Years to 75 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 21, 2026, 10:14 AM EDT
Recruiting Not applicable Interventional

A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial

NCT05805709
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Study Physician/Advance Practice Provider, Nurse Navigator, Pharmacist, Patient Education
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
2,145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
9
States / cities
Birmingham, Alabama • New Haven, Connecticut • Weston, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Phase 4 Interventional Results available

Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients

NCT01427907
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Calcium acetate oral solution (COS), Sevelamer carbonate
Drug
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
New Haven, Connecticut • North Haven, Connecticut • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics of VI-0521 Subjects With Renal Impairment

NCT00768404
View directory record Official record
Conditions
Renal Impairment
Interventions
Topirmate and Phentermine
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
19 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
Anaheim, California • Miami, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2009 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Not applicable Interventional

Effects of Lowering Dialysate Calcium Level on Progression of Coronary Artery Calcification and Bone Histomorphometry

NCT00297219
View directory record Official record
Conditions
End-Stage Renal Disease, Hemodialysis
Interventions
Low dialysate calcium, high dialysate calcium
Drug
Lead sponsor
Ege University
Other
Eligibility
18 Years to 80 Years
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 4, 2009 · Synced Oct 21, 2026, 10:14 AM EDT
Recruiting Phase 1 Interventional

Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function

NCT06623630
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cyclophosphamide, Ciltacabtagene Autoleucel, Total body irradiation
Drug · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 21, 2026, 10:14 AM EDT
Completed No phase listed Observational

Inferior Vena Cava (IVC) Size in Acute Renal Failure

NCT02064244
View directory record Official record
Conditions
Acute Renal Failure
Interventions
Ultrasound for measurement of Inferior Vena Cava size.
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 9, 2016 · Synced Oct 21, 2026, 10:14 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression

NCT06866236
View directory record Official record
Conditions
Chronic Kidney Diseases, Acute Kidney Injury, Kidney Failure
Interventions
QRX-3
Drug
Lead sponsor
Ebima Clifford Okundaye
Industry
Eligibility
18 Years to 90 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pasedena, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 21, 2026, 10:14 AM EDT
Terminated Phase 4 Interventional

The Effect of Epogen and Venofer Dosing Management on Hemoglobin Stability

NCT01975844
View directory record Official record
Conditions
Anemia, End Stage Renal Disease
Interventions
Individualized Anemia Mangement Protocol
Other
Lead sponsor
Michael Germain
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Chicopee, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Oct 21, 2026, 10:14 AM EDT
Terminated Phase 4 Interventional Results available

Does An Abnormal PFA 100 Predict Bleeding After Renal Biopsy?

NCT00334204
View directory record Official record
Conditions
Kidney Failure, Acute, Kidney Failure, Chronic, Blood Platelet Disorders, Hemorrhage
Interventions
measuring Platelet Function Analyser-100 (PFA-100) platelet function before kidney biopsy
Device
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Not applicable Interventional Results available

Feasibility Study for Heparin-free Hemodialysis With the Dialyzer With Endexo™

NCT04511338
View directory record Official record
Conditions
Chronic Kidney Diseases, Patient Requiring Heparin Free Dialysis Treatments
Interventions
Dialyzer with Endexo
Device
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
22 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
New Bern, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Oct 21, 2026, 10:14 AM EDT
Completed No phase listed Observational

Kidney Precision Medicine Project (KPMP) - COVID-19 Protocol

NCT05384899
View directory record Official record
Conditions
Acute Kidney Failure, Acute Kidney Insufficiency, Acute Renal Failure, Acute Renal Injury, Acute Renal Insufficiency, Kidney Failure, Acute, Kidney Insufficiency, Acute, Renal Failure, Acute, Renal Insufficiency, Acute, Covid19, Sars-CoV-2 Infection
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Not applicable Interventional

The Optiflow Patency and Maturation Study

NCT01921933
View directory record Official record
Conditions
End-stage Kidney Disease, End-stage Renal Disease
Interventions
Optiflow
Device
Lead sponsor
Bioconnect Systems, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Phase 3 Interventional Results available

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)

NCT03029208
View directory record Official record
Conditions
Anaemia
Interventions
Daprodustat, Darbepoetin alfa, Iron therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 99 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
36
States / cities
Anaheim, California • Cerritos, California • Escondido, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Oct 21, 2026, 10:14 AM EDT
Recruiting No phase listed Observational

QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry

NCT06517810
View directory record Official record
Conditions
Acute Kidney Injury, Acute Kidney Injury Due to Sepsis
Interventions
QUELIMMUNE (SCD-PED)
Device
Lead sponsor
SeaStar Medical
Industry
Eligibility
Up to 22 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
15
States / cities
Birmingham, Alabama • Palo Alto, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 21, 2026, 10:14 AM EDT